NEUROPROTECTIVE EFFECTS OF D - PENICILLAMINE IN THE NEONATAL PERIOD
Originally D-penicillamine (D-PA) was used due to its potential benefits in the treatment of neonatal hyperbilirubinemia caused by hemolytic diseases in newborn infants or immaturity of the liver enzyme uridine 5'-diphospho-glucuronosyltransferase (UDP-glucuronosyltransferase). In that period, the prevalence of retinopathy of prematurity (ROP) in infants who received treatment with D-PA. Later, studies were performed by different institutes in Poland, Hungary, the USA, Mexico, and India. Short or long-term use of the medication didn’t seem to have caused toxicity or intolerance, even D-PA in the newborn period was given in higher doses compared with the doses used in adult patients. Several bilirubin-induced neurologic dysfunctions in the infants, including ROP and autism spectrum disorder, are possibly caused by metal accumulation, unconjugated bilirubin (UCB), as well as UCB-copper complexes in sensitive regions of the central nervous system. Apparently, neonatal hemolysis of red blood cells leads to an unphysiological release of copper and iron from the cells, which pass the blood-brain-barrier (BBB) via the bloodstream. Also, reactive oxygen species contributing to an increased BBB permeability, which creates a dangerous vicious circle in the neonatal brain. In this paper, we present two cases of neonatal hyperbilirubinemia, which indicate the potential neuroprotective effects of D-PA.
Lajos Lakatos1*, Jan Aaseth2,3, Maryam Dadar4, Geir Bjørklund5*
1 Department of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary;
2 Research Department, Innlandet Hospital Trust, Brumunddal, Norway;
3 IM Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
4 Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran;
5 Council for Nutritional and Environmental Medicine (CONEM), Mo i Rana, Norway
1. Aaseth J. Experimental copper chelation: clinical implications // Erudite J Drugs. 2012;1:1-3.
2. Almandil N.B., Alkuroud D.N., AbdulAzeez S., Al Sulaiman A., Elaissari A., Borgio J.F. Environmental and genetic factors in autism spectrum disorders: Special emphasis on data from Arabian studies // Int J Environ Res Public Health. 2019;16(4):658.
3. Ayala A., Muñoz M.F., Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal // Oxid Med Cell Longev. 2014;2014.
4. Bjørklund G. The role of zinc and copper in autism spectrum disorders // Acta Neurobiol Exp (Wars). 2013;73(2):225-36.
5. Bjørklund G., Chartrand M. Nutritional and environmental influences on autism spectrum disorder // J Nutr Disorders The. 2016;6:e123.
6. Bjørklund G., Saad K., Chirumbolo S., Kern J.K., Geier D.A., Geier M.R. et al. Immune dysfunction and neuroinflammation in autism spectrum disorder // Acta Neurobiol Exp (Wars). 2016;76(4):257-68.
7. Brooks D., Asta K., Sturza J., Kebede B., Bekele D., Nigatu B. et al. Patient preferences for prenatal testing and termination of pregnancy for congenital anomalies and genetic diseases in Ethiopia // Prenat Diagn. 2019; 39(8):595-602.
8. Cao Y., Skaug M.A., Andersen O., Aaseth J. Chelation therapy in intoxications with mercury, lead and copper // J Trace Elem Med Biol. 2015;31:188-92.
9. Chen L., Wang W.-J., Auger N., Xiao L., Torrie J., McHugh N.G.-L. et al. Diabetes in pregnancy in associations with perinatal and postneonatal mortality in First Nations and non-Indigenous populations in Quebec, Canada: population-based linked birth cohort study // BMJ Open. 2019;9(4):e025084.
10. Chowrimootoo G., Scowcroft H., Seymour C.A. Caeruloplasmin isoforms in Wilson’s disease in neonates // Archives of Disease in Childhood-Fetal and Neonatal Edition. 1998;79(3):F198-F201.
11. Christensen R., Alder S., Richards S., Lambert D., Schmutz N., Wiedmeier S. et al. D-Penicillamine administration and the incidence of retinopathy of prematurity // J Perinatol. 2007;27(2):103.
12. Goldstein B.D., Harber L.C. Erythropoietic protoporphyria: lipid peroxidation and red cell membrane damage associated with photohemolysis // J Clin Invest. 1972;51(4):892-902.
13. Hadjivasiliou A. Evaluate Pharma // Orphan Drug Report. 2014. 20.15.
14. Horn N., Møller L.B., Nurchi V.M., Aaseth J. Chelating principles in Menkes and Wilson diseases: Choosing the right compounds in the right combinations at the right time // J Inorg Biochem. 2018.
15. Jomova K., Valko M. Advances in metal-induced oxidative stress and human disease // Toxicology. 2011;283(2-3):65-87.
16. Kandanapitiye M.S., Gunathilake C., Jaroniec M., Huang S.D. Biocompatible D-penicillamine conjugated Au nanoparticles: targeting intracellular free copper ions for detoxification. J Mater Chem B. 2015;3(27):5553-9.
17. Lakatos L., Balla G. D-Penicillamine in the neonatal period. LAP Lambert Academic Publishing. 2016.
18. Lakatos L., Kövér B. Az újszülöttkori hyperbilirubinaemiák D-Penicillamin therapiája. D-Penicillamine Therapy In Neonatal Hyperbilirubinaemias // A Preliminary Report. Orv Hetil (Hungarian J Med). 1974;115:307-11.
19. Lakatos L., Balla G., Pataki I. Copper-induced oxidative/nitrosative stress and excitoxicity in the neonatal period: neuroprotection with D-Penicillamine // Pediatr Dimens. 2017;2:1-6.
20. Lakatos L. Penicillamine-Preventing or. Curing” Autism Spectrum Disorders in the Neonatal Period. 2017:51-2.
21. Macedoni-Lukšič M., Gosar D., Bjørklund G., Oražem J., Kodrič J., Lešnik-Musek P. et al. Levels of metals in the blood and specific porphyrins in the urine in children with autism spectrum disorders // Biol Trace Elem Res. 2015;163(1-2):2-10.
22. Maines M.D., Kappas A. Metals as regulators of heme metabolism // Science. 1977;198(4323):1215-21
23. Martínez A., Reina M. Copper or free radical scavenger? // Computational and Theoretical Chemistry. 2017;1104:1-11.
24. Meguid N.A., Anwar M., Bjørklund G., Hashish A., Chirumbolo S., Hemimi M. et al. Dietary adequacy of Egyptian children with autism spectrum disorder compared to healthy developing children // Metab Brain Dis. 2017;32(2):607-15.
25. Nagy A., Felszeghi E. Per os D-Penicillaminnal és fototerápiával sikeresen kezelt Rh-isoimmunisation // Gyermekgyógyászat. 2000;51:81-3.
26. Nimse S.B., Pal D. Free radicals, natural antioxidants, and their reaction mechanisms // Rsc Advances. 2015;5(35):27986-8006.
27. Öhrvik H., Aaseth J., Horn N. Orchestration of dynamic copper navigation–new and missing pieces // Metallomics. 2017;9(9):1204-29.
28. Pasupathy D., Denbow M., Rutherford M. Obstetricians RCo, Gynaecologists. The Combined Use of Ultrasound and Fetal Magnetic Resonance Imaging for a Comprehensive Fetal Neurological Assessment in Fetal Congenital Cardiac Defects: Scientific Impact Paper No. 60. // BJOG: An International Journal of Obstetrics & Gynaecology. 2019;126(7):e142-e51.
29. Pataki I., Balla G., Nagy A., Berkes A., Szolos A. Long-term follow up of patients treated with D-Penicillamine in the neonatal period // J Neonatal Biol. 2018;7(270):2167-0897.1000270.
30. Perrone S., Tataranno M.L., Stazzoni G., Buonocore G. Oxidative stress and free radicals related diseases of the newborn // Adv Biosci Biotechnol. 2012;3(07):1043
31. Perry G., Sayre L.M., Atwood C.S., Castellani R.J., Cash A.D., Rottkamp C.A. et al. The role of iron and copper in the aetiology of neurodegenerative disorders // CNS drugs. 2002;16(5):339-52.
32. Phaniendra A., Jestadi D.B., Periyasamy L. Free radicals: properties, sources, targets, and their implication in various diseases // Indian journal of clinical biochemistry. 2015;30(1):11-26.
33. Qureshi M.J., Kumar M. D‐Penicillamine for preventing retinopathy of prematurity in preterm infants // Cochrane Database Syst Rev. 2013(9). https://doi.org/10.1002/14651858.CD001073.pub2
34. Rohlman D.S., Ismail A., Bonner M.R., Rasoul G.A., Hendy O., Dickey L.O. et al. Occupational pesticide exposure and symptoms of attention deficit hyperactivity disorder in adolescent pesticide applicators in Egypt // Neuro Toxicology. 2019;74:1-6.
35. Sirivichayakul S., Kanchanatawan B., Thika S., Carvalho A.F., Maes M. A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions // CNS Neurol Disord Drug Targets. 2019;18(2):124-40.
36. Skalny A.V., Simashkova N.V., Klyushnik T.P., Grabeklis A.R., Bjørklund G., Skalnaya M.G. et al. Hair toxic and essential trace elements in children with autism spectrum disorder // Metab Brain Dis. 2017;32(1):195-202.
37. Stocks J., Offerman E., Modell C., Dormandy T. The susceptibility to autoxidation of human red cell lipids in health and disease // Br J Haematol. 1972;23(6):713-24.
38. Strunecka A., Strunecky O. Chronic Fluoride Exposure and the Risk of Autism Spectrum Disorder // Int. J Environ Res Public Health. 2019;16(18):3431.
39. Tandon M., Dutta S., Dogra M.R., Gupta A. Oral D‐penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo‐controlled trial // Acta Pædiatrica. 2010;99(9):1324-8.
40. Walker L.R., Rattigan M., Canterino J. A case of isolated elevated copper levels during pregnancy // J. Pregnancy. 2011;2011.
Количество просмотров: 652
Категория статей:
Клинический случай
Библиографическая ссылка
Lajos Lakatos, Jan Aaseth, Maryam Dadar, Geir Bjørklund Нейропротекторные эффекты Д – пеницилламина в неонатальном периоде // Наука и Здравоохранение. 2019. 5 (Т.21). С. 116-120.Похожие публикации:
ACTIVATION OF OPPOSITE PROCESSES – OSTEOPOROSIS AND OSTEOGENESIS IN ANKYLOSING SPONDYLITIS USING THE CLINICAL CASES
RABIES - AN INFECTIOUS DISEASE WITH A FATAL OUTCOME (CLINICAL CASE)
ГРАНУЛЕМАТОЗНЫЙ ПОЛИАНГИИТ (ГРАНУЛЕМАТОЗ ВЕГЕНЕРА) В ПРАКТИКЕ РЕВМАТОЛОГА
ВАРИАНТ ТЕЧЕНИЯ БОЛЕЗНИ СТИЛЛА ВЗРОСЛЫХ: КЛИНИЧЕСКИЙ СЛУЧАЙ
A CASE OF DÜHRING'S DERMATITIS HERPETIFORMIS ASSOCIATED WITH SARS - COV - 2